Your search history is turned on.
Date: April 26, 2024 Jurisdictions: All jurisdictions
Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 26, 2024 -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the Company or Appili), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasu...
Date: April 8, 2024 Jurisdictions: All jurisdictions
NATDOCS\77919817\V-1 ARRANGEMENT AGREEMENT BETWEEN APPILI THERAPEUTICS INC. AND ADITXT, INC. AND ADIVIR, INC. DATED AS OF April 1, 2024 TABLE OF CONTENTS Page ARTICLE I INTERPRETATION..................................................................................................................... 1 Section 1.01 Definitions .......................................................................................................
Form Settled NATDOCS\60779237\V-7 SUPPORT AND VOTING AGREEMENT THIS AGREEMENT is made as of the 1st day of April, 2024. BETWEEN: [] (the "Company Securityholder") - and - Adivir, Inc., a corporation existing under the laws of the State of Delaware (the "Buyer") WHEREAS Appili Therapeutics Inc., a corporation incorporated under the laws of the Canada (the "Company"), Aditxt, Inc., a corporation existing ...
Microsoft Word - Project Cubed - Material Change Report.docx NATDOCS\77939830\V-2 FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company Appili Therapeutics Inc. (the Company) #21-1344 Summer Street Halifax, NS B3H 0A8 2. Date of Material Change April 1, 2024. 3. News Release A news release dated April 2, 2024, was dissemin...
Date: April 2, 2024 Jurisdictions: All jurisdictions
Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc. Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 02, 2024 -- App...
Date: March 12, 2024 Jurisdictions: All jurisdictions
Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks A review of Russian and English literature suggests that Appilis biodefense program ATI-1701 may have a role in preventing tularemia in Ukraine HALIFAX, Nova Scotia, March 12, 2024 -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the Company or Appili), a biopharmaceutical company focused on dr...
Date: February 14, 2024 Jurisdictions: All jurisdictions
Microsoft Word - Appili Reports Financial Results Q3 FY2024 - 240213 FINAL Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024 FDA approved LIKMEZ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL Additional USAFA funding commitment from the U.S. Air Force Academy, intended to advance the ATI-1701 progra...
Date: February 13, 2024 Jurisdictions: All jurisdictions
1 Form 52-109F2 Certification of Interim Filings Full Certificate I, Kenneth Howling, Acting Chief Financial Officer of Appili Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Appili Therapeutics Inc. (the issuer) for the interim period ended December ...
Form 52-109F2 Certification of Interim Filings Full Certificate I, Don Cilla, Chief Executive Officer of Appili Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Appili Therapeutics Inc. (the issuer) for the interim period ended December 31, 2023. ...
MANAGEMENTS DISCUSSION AND ANALYSIS For the Interim Period Ended December 31, 2023 1 APPILI THERAPEUTICS INC. The following Managements Discussion and Analysis (MD&A) of Appili Therapeutics Inc...